ENAVATE SCIENCES GP, LLC
Long book
$351.5M
Q1 2026
Positions
7
Top-10 weight
100%
concentration
Last quarter
+4.8%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsENAVATE SCIENCES GP, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $351.5M US long book across 7 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: SIONNA THERAPEUTICS INC, IMMUNOME INC, ZENAS BIOPHARMA INC, COMPASS THERAPEUTICS INC, BRIDGEBIO ONCOLOGY THERAPEUT.
Over the last 6 quarters its long book ran on average 13pp per quarter ahead of the S&P 500, beating the index in 3 of 6 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-29.5%
Q1 2025
+33.0%
Q2 2025
+68.3%
Q3 2025
+54.4%
Q4 2025
-24.9%
Q1 2026
+4.8%
Sector allocation
Healthcare 100%
Long book by quarter
What does ENAVATE own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| SION SIONNA THERAPEUTICS INC | Healthcare | 2.5M | $99.3M | 28.3% | Held |
| IMNM IMMUNOME INC | Healthcare | 3.6M | $79.0M | 22.5% | -24.2% |
| ZBIO ZENAS BIOPHARMA INC | Healthcare | 3.9M | $76.6M | 21.8% | Held |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 7.8M | $41.2M | 11.7% | Held |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | Healthcare | 2.6M | $23.5M | 6.7% | Held |
| UPB UPSTREAM BIO INC | Healthcare | 2.5M | $22.1M | 6.3% | Held |
| CAMP CAMP4 THERAPEUTICS CORP | Healthcare | 2.2M | $9.7M | 2.7% | -27.8% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 7 | $351.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 7 | $506.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 7 | $327.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 6 | $176.5M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 6 | $132.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 5 | $139.2M | canonical | SEC ↗ |